HeartSciences (NASDAQ:HSCS) Stock Price Expected to Rise, Ascendiant Capital Markets Analyst Says

HeartSciences (NASDAQ:HSCS) had its target price hoisted by investment analysts at Ascendiant Capital Markets from $9.00 to $9.20 in a report released on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Ascendiant Capital Markets’ price objective indicates a potential upside of 248.48% from the stock’s current price.

Several other research analysts also recently issued reports on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of HeartSciences in a research note on Monday, December 15th. Wall Street Zen upgraded shares of HeartSciences from a “sell” rating to a “hold” rating in a report on Friday, October 3rd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, HeartSciences has a consensus rating of “Hold” and an average target price of $9.20.

HeartSciences Price Performance

Shares of NASDAQ:HSCS opened at $2.64 on Monday. The business has a fifty day moving average price of $2.83 and a 200-day moving average price of $3.36. The company has a market capitalization of $8.40 million, a PE ratio of -0.38 and a beta of 2.57. HeartSciences has a 1-year low of $2.01 and a 1-year high of $6.47.

HeartSciences (NASDAQ:HSCS) last announced its quarterly earnings results on Monday, December 15th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.05. The firm had revenue of $2.42 million during the quarter, compared to the consensus estimate of $0.00 million. On average, sell-side analysts anticipate that HeartSciences will post -10.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On HeartSciences

An institutional investor recently bought a new position in HeartSciences stock. Geode Capital Management LLC purchased a new stake in shares of HeartSciences Inc. (NASDAQ:HSCS) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 11,599 shares of the company’s stock, valued at approximately $43,000. Geode Capital Management LLC owned 0.51% of HeartSciences as of its most recent SEC filing. Institutional investors and hedge funds own 17.24% of the company’s stock.

About HeartSciences

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.